Hormone therapyFDA-approvedSecond-line
Fulvestrant
How it works
Blocks the estrogen receptor on cancer cells, preventing growth signals and inhibiting cell division.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
In clinical trials, around 20% of hormone receptor-positive patients achieved an objective response, with median progression-free survival of approximately 5 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Fulvestrant-Treated Breast Cancer Cells: New Targets for Treatment | Breast Cancer | lab-study | — | Source → |
| Advanced Breast Cancer Treatment Trial: Endocrine Therapy Plus CDK4/6 Inhibitor | Breast Cancer | phase-3 | — | Source → |
| Study of Inavolisib and Fulvestrant in Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| PF-07248144 and Fulvestrant Combination for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing New Combination Treatments for Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing IDE574 Therapy for Advanced Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Evaluating TQB3616 Capsules for Recurrent/Metastatic Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Belzutifan and Fulvestrant for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating Giredestrant for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Evaluating Two Doses of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Combining treatments may help hormone receptor-positive breast cancer | Breast Cancer | animal-study | Fulvestrant emerged as the most effective treatment, inducing regression of most existing tumors and reducing on-treatment tumor burden when combined with αPD-L1. | Source → |
| Fulvestrant May Help Control Low-Grade Gynecological Cancers | Ovarian Cancer | phase-2 | Fulvestrant may control tumor growth in recurrent/metastatic estrogen receptor-positive low-grade gynecological malignancies of specific histology. | Source → |
| PFKFB3's Role in Breast Cancer Growth and Treatment | Breast Cancer | lab-study | The growth of ER-positive breast cancer cells in vivo was more potently inhibited by fulvestrant combined with the PFKFB3 inhibitor PFK158 than for each drug alone. | Source → |
| New Resistance Mechanism Found in Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Fulvestrant treatment in breast cancer: what predicts long-term benefit | Breast Cancer | observational | The 18-month progression-free survival rate was 27%. | Source → |
| Switching to Fulvestrant Improves Cancer Treatment Outcomes | Breast Cancer | phase-3 | The strategy of switching to palbociclib plus fulvestrant more than doubled progression-free survival. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.